Lapatinib (Tykerb) tab 250 mg: Discontinuation

Due to decreasing demand for lapatinib, Novartis (the supplier) is discontinuing it (pharmacode 2265508).

No new patients from 1 April 2021

We were initially going to delist this product from the HML and Schedule on 1 June 2021. However, because a small number of patients started taking lapatinib, we changed our approach. 

Since 1 April 2021, prescribers cannot submit an initial Special Authority application. We will delist lapatinib from the Schedule and HML at a later date.

We expect this to affect fewer than 10 patients. 

Ample supply for current patients

Novartis anticipates no problem with ongoing supply for existing patients. People on lapatinib can remain on this treatment.

Who to contact

If you have any questions about this discontinuation, email